Attendees walk past the Merck logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, US June 23, 2026. | Photo Credit: MIKE BLAKE
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $11.3 billion, the German science and healthcare firm said in a statement on Thursday.
Shares of Bio-Techne rose 22 per cent in premarket trading.
The offer price of $73 per share implies a 24 per cent premium to Bio-Techne’s close on Wednesday.
The acquisition would expand Merck’s presence in life-science research. Bio-Techne supplies research reagents, proteins, antibodies, analytical instruments and other tools used by scientists and drug developers.
The German firm said it would fund the acquisition through a combination of existing cash and new debt.
Published on June 25, 2026
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。